RVTY241115P180000
- 0.00
- 0.000.00%
Revvity Newsroom
Revvity | 10-Q: Quarterly report
Revvity's Resilience and Growth Potential: A Buy Rating Amidst Challenges
Revvity's Valuation Seen Fair on Medium-Term Setup -- Market Talk
These Analysts Revise Their Forecasts On Revvity Following Q3 Results
Revvity Is Maintained at Outperform by Raymond James
UBS Raises Revvity Price Target to $145 From $140, Maintains Neutral Rating
Raymond James Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $146
Beam Falls After Fatality in Gene Editing Trial
TD Cowen Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $144
Bernstein Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $145
Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN), Editas Medicine (EDIT) and Revvity (RVTY)
Express News | Revvity Inc : Bernstein Cuts Target Price to $145 From $150
A Quick Look at Today's Ratings for Revvity(RVTY.US), With a Forecast Between $132 to $145
Baird Maintains Outperform on Revvity, Raises Price Target to $138
Revvity Analyst Ratings
US stocks gold digging | Delayed increase in oil production boosts oil prices! Oil and gas pipeline operator TRGP has surged nearly double in a year; outstanding performance boosts stock price! Media giant Fox Corporation hits nearly a 5-year high.
Potash production may be reduced? Belarusian President plans to raise the price of potash, fertilizer giant Nutrien hits a new high since August; pet product retailer Chewy joins the S&P MidCap 400 index, surging over 6% overnight.
Barclays Reaffirms Their Buy Rating on Revvity (RVTY)
Revvity Reports Strong Q3 Growth and New Share Buyback
Revitty (RVTY) Q3 2024 Earnings Call Transcript
Evercore ISI Adjusts Price Target on Revvity to $134 From $132